Phoenix Molecular Designs Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Phoenix Molecular Designs's estimated annual revenue is currently $4.2M per year.(i)
  • Phoenix Molecular Designs's estimated revenue per employee is $155,000

Employee Data

  • Phoenix Molecular Designs has 27 Employees.(i)

Phoenix Molecular Designs's People

NameTitleEmail/Phone
1
Chief Operating OfficerReveal Email/Phone
2
Chief Medical Officer, San Diego OperationsReveal Email/Phone
3
Chief Scientific OfficerReveal Email/Phone
4
CMC-API Consultant – San Diego OperationsReveal Email/Phone
5
Senior Research ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Phoenix Molecular Designs?

keywords:N/A

N/A

Total Funding

27

Number of Employees

$4.2M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Phoenix Molecular Designs News

2022-04-20 - HER2 negative Breast Cancer Pipeline Insights | Research Report 2022 by DelveInsight

... Ayala Pharmaceuticals, Inc., ERYtech Pharma, SynCore Biotechnology Co., Ltd., Phoenix Molecular Designs, Chipscreen Biosciences, Ltd.,...

2022-04-20 - HER2 negative Breast Cancer Pipeline Insights | Research ...

... Ltd., Phoenix Molecular Designs, Chipscreen Biosciences, Ltd., ... By HER2 negative Breast Cancer Therapies Molecule Type: Gene therapy,...

2022-04-20 - HER2 negative Breast Cancer Pipeline Insights | Research Report 2022 by DelveInsight - Benzinga

... Ltd., Phoenix Molecular Designs, Chipscreen Biosciences, Ltd., ... Cancer Therapies Molecule Type: Gene therapy, Stem cell therapy,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.2M27-7%N/A
#2
$4.6M270%N/A
#3
$2.8M2717%$11.6M
#4
$2.5M27-32%N/A
#5
$4.6M27-10%N/A